Ekuinas enters pharma industry with Medispec acquisition


Ekuinas chief executive officer Syed Yasir Arafat Syed Abd Kadir said Ekuinas’ entry into the healthcare and pharmaceutical space was timely as it looked to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19.

KUALA LUMPUR: Ekuiti Nasional Bhd (Ekuinas) made its foray into the pharmaceutical industry with the acquisition of a controlling stake in Medispec (M) Sdn Bhd.

The government-linked private equity fund management company said the acquisition was based on an enterprise value of RM88.5mil.

Ekuinas chief executive officer Syed Yasir Arafat Syed Abd Kadir said Ekuinas’ entry into the healthcare and pharmaceutical space was timely as it looked to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19.

“Medispec is one of the leading distributors and marketers of healthcare and pharmaceutical products in Malaysia with a track record of over 35 years.

“It has established a strong supply chain and distribution network in the local market, driven by their deep industry knowledge and strong relationship with principals.

“We are happy to be part of the next phase of its journey, ” he said in a statement.

Syed Yasir Arafat added that apart from Medispec’s large established distribution network across clinics, pharmacies, private and public hospitals, other key considerations contributing to Ekuinas’ decision to invest in the company include favourable industry outlook, in-house brand with strong growth prospects and healthy product pipeline.

He stressed these factors will be important in charting Medispec’s future growth plans.

Medispec, which turns 35 this year, markets more than 100 pharmaceutical drugs and 30 health supplements under both prescription and over-the-counter (OTC) categories.

These include medical applications covering various therapeutic areas such as anti-infectives, antineoplastic, musculo-skeletal system, cardiovascular system and nervous system.

It also owns Vitamode, an award-winning in-house health supplement brand, which features specialty products such as CoQ10 Ubiquinol, Mecobin, Lacidofil, Cognipro and Tumecap.

Medispec CEO Teng Beng Lee said the company was pleased to be part of Ekuinas’ portfolio and that he was confident in working with them to venture into the next phase of growth.

“Apart from growing our home-grown supplement brand Vitamode domestically, we are poised to take our brand regionally to Asean countries by leveraging Ekuinas’ expertise. “Learning from the pandemic, we will also be putting greater focus on online marketing channels to reach our consumers, ” he said.

In the same statement, Ekuinas said its entry into the pharmaceutical industry was highly cognisant of the macro themes at play.

In line with growing healthcare awareness amongst consumers, it anticipated the post-pandemic world to see a significant shift from remedial to preventive healthcare measures

Ekuinas has made investments in 42 companies since its inception in 2009 with a total committed investment of RM4.4bil.

With that, it has also generated a positive impact on the broader Malaysian economy, which facilitated a total economic deployment of RM5bil, together with private sector partners.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In Business News

Bullish investors push copper price towards 10-year highs
United Airlines loss bigger than feared on higher fuel costs, capacity slide
US warns airlines on flights near Ukraine-Russian border
Oil price climbs as US$ slumps; gains capped by pandemic surge
GLOBAL MARKETS-World shares dip after hitting record highs
Boustead in revamp deals
Credit Suisse serves investors thin gruel as Wall Street feasts on deals
Govt wants to promote kenaf building system
Aviation seeing healthy growth in cargo segment
KRC attracts over RM2.2bil in investments

Stories You'll Enjoy


Vouchers